Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Michael de Manincor

3 papers in the library · 266 citations · publishing 2020-2025

Papers

Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants

Psychopharmacology January 11, 2021 Nicole Leite Galvão‐coelho, Wolfgang Marx, Maria González et al. 143 citations

Classic serotonergic psychedelics such as psilocybin, LSD, and ayahuasca may improve mood and reduce depressive symptoms more than placebo, with effects appearing within hours and lasting up to 60 days. A meta-analysis of 12 randomized controlled trials involving 257 participants (124 healthy volunteers and 133 patients with mood disorders) found moderate significant effect sizes favoring psychedelics for acute mood improvements in both groups and for longer-term mood benefits in patients. For patients with mood disorders, significant reductions in depressive symptoms were seen acutely, at 2–7 days, and at 16–60 days after treatment. Although unblinding and expectancy are concerns, the strength, speed, and durability of effects support further placebo-controlled trials.

Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties

Journal of Translational Medicine October 2, 2020 Lara Sharpe, Justin Sinclair, Andrew Kramer et al. 122 citations

Acute doses of cannabidiol (CBD) reduce anxiety in both animals and humans without causing anxiety at higher doses, while tetrahydrocannabinol (THC) commonly produces anxiety, especially at higher doses. Epidemiological studies support an anxiolytic effect from CBD, THC, or whole-plant cannabis, but human clinical studies show THC often triggers anxiogenic responses. Cannabinoid therapies containing primarily CBD may be more suitable for people with pre-existing anxiety or as an adjunct for managing anxiety or stress-related disorders. Further research is needed on other cannabis constituents like terpenes, and more clinical trials involving patients with anxiety disorders are warranted.

Consensus-Based Recommendations for Yoga as Adjunct Therapy in Eating Disorder Treatment: A Delphi Study.

The International journal of eating disorders June 1, 2025 Eleanor Trethewey, Subhadra Evans, Shane Mciver et al. 1 citation

Experts in eating disorders and yoga instructors agreed on key considerations for safely and therapeutically applying yoga to anorexia nervosa, bulimia nervosa, and binge-eating disorder. Using a two-round modified Delphi technique, 12 clinicians and 16 yoga instructors (with 10 and 13 completing the second round) rated the importance of yoga components such as style, frequency, duration, environment, safety precautions, language, instructor qualifications, postures, breathwork, and meditation. General recommendations were organized into six core areas: yoga style, environmental factors, dosage, language and expression, the instructor's role, and integration into treatment. Technique-specific recommendations addressed postures, breathwork, and meditation across the eating disorder spectrum. The findings emphasize trauma-informed, individualized approaches and highlight the need for further research to develop comprehensive guidelines.